Corporate Events

SpyGlass Pharma, Inc. (NasdaqGS:SGP) acquired Advanced Vision Science, Inc. from Santen Pharmaceutical Co., Ltd. (TSE:4536) for $13 million on October 1, 2026. A cash consideration of $13 million will be paid by SpyGlass Pharma, Inc. As part of consideration, $13 million is paid towards common equity of Advanced Vision Science, Inc. The purchase price is subject to a customary post-closing adjustment. Prior to the acquisition, Advanced Vision Science was SpyGlass Pharma, Inc.'s supplier of intraocular lenses. Post-acquisition, Advanced Vision Science will operate as a subsidiary and continue to manufacture and supply intraocular lens products to its former parent, Santen Pharmaceutical Co., Ltd., for commercialization in Japan. Additionally, Advanced Vision Science will continue to license its glistening-free hydrophobic acrylic lens material to Bausch + Lomb. Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor for SpyGlass Pharma, Inc. MTS Health Partners, L.P. acted as financial advisor for Santen Pharmaceutical Co., Ltd. Squire Patton Boggs LLP acted as legal advisor for Santen Pharmaceutical Co., Ltd. Gitkin & Co. acted as financial advisor for SpyGlass Pharma, Inc. SpyGlass Pharma, Inc. (NasdaqGS:SGP) completed the acquisition of Advanced Vision Science, Inc. from Santen Pharmaceutical Co., Ltd. (TSE:4536) on October 1, 2026.

Santen Pharmaceutical Co., Ltd., ¥ 21.0, Cash Dividend, Sep-29-2026

KYORIN Pharmaceutical Co., Ltd. announced that it has entered into joint marketing agreement in Japan for Alesion eyelid cream 0.5%, (generic name: epinastine hydrochloride, hereinafter Alesion Cream), a long-acting treatment for allergic conjunctivitis with Santen Pharmaceutical Co., Ltd. Alesion Cream is a treatment for allergic conjunctivitis developed by Santen with the aim of improving patient adherence and reducing treatment burden compared with conventional anti-allergic eye drops. As a cream formulation applied once daily to the periocular area (upper and lower eyelids), it has been marketed in Japan since May 22, 2024. Under the agreement, Santen will continue to be responsible for manufacturing, product distribution, and detailing for medical institutions specializing in the field of ophthalmology, with KYORIN handling detailing for medical institutions outside this field from around August 2026. The two partners—KYORIN, with expertise in allergic diseases and a strong sales and marketing platform in the respiratory and otolaryngology fields, and Santen, a company specialized in ophthalmology, expect the joint marketing agreement to enable them to deliver Alesion Cream, a new treatment option for allergic conjunctivitis, to as many patients as possible, thereby contributing to improved patient quality of life (QOL). If any matters arise that require timely disclosure regarding the impact of this matter on the consolidated earnings forecast for the fiscal year ending March 31, 2027, KYORIN will promptly announce them.

Santen Pharmaceutical Co., Ltd., Q1 2027 Earnings Call, Aug 06, 2026

Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 06, 2026

Santen Pharmaceutical Co., Ltd. proposed year-end dividend of JPY 19.00 per share for the fiscal year ended March 31, 2026 compared to JPY 19.00 per share paid a year ago. Annual Shareholders Meeting (Scheduled): June 23, 2026. Start of Distribution of Dividends (Scheduled): June 24, 2026.

Santen Pharmaceutical Co., Ltd. expects dividend of JPY 21.00 for second quarter-end of fiscal year ending March 31, 2027 as compared to JPY 19.00 per share paid a year ago. For year-end of fiscal year ending March 31, 2027, the Company expects to pay dividend of JPY 21.00 per share as compared to JPY 19.00 same period prior year.

Santen Pharmaceutical Co., Ltd. provided consolidated earnings guidance for fiscal year ending March 31, 2027. For the year, the company expects Revenue of JPY 311,000 million, Operating Profit of JPY 49,500 million, Net profit for the year of JPY 39,500 million and basic earnings per share of JPY 124.42.

Santen Pharmaceutical Co., Ltd. expected to report Q1 2027 results on August 5, 2026. This event was calculated by S&P Global (Created on May 14, 2026).

Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.

Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026

Santen Pharmaceutical Co., Ltd., 2026 Earnings Call, May 12, 2026

Product Development Meeting

Santen Pharmaceutical Co., Ltd. reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 210,763 million compared to JPY 222,773 million a year ago. Net income was JPY 21,816 million compared to JPY 27,465 million a year ago. Basic earnings per share from continuing operations was JPY 66.16 compared to JPY 78.21 a year ago. Diluted earnings per share from continuing operations was JPY 66.05 compared to JPY 77.98 a year ago.

Santen Pharmaceutical Co., Ltd. expected to report Fiscal Year 2026 results on May 12, 2026. This event was calculated by S&P Global (Created on April 22, 2026).

Santen Pharmaceutical Co., Ltd., Q3 2026 Earnings Call, Feb 05, 2026

RVL Pharmaceuticals Inc. and its affiliates announced Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ®? Mini Ophthalmic Solution 0.1% (generic name:oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids). This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. In the U.S. market, Upneeq®? is the first and only FDA-approved prescription eye drop for acquired blepharoptOS (low-lying eyelids), and continues to demonstrate strong patient satisfaction, increased adoption, and channel diversification. The superiority of the product was demonstrated in the primary endpoint - a change from baseline at 2 hours after administration in MRD-1 (Marginal Reflex Distance-1, the margin between the upper eyelid and the center of the pupil) at Day 14 after the start of treatment--in the once-daily group versus the placebo eye drop group. In addition, an exploratory analysis showed that improvement in MRD-1 persisted for more than 8 hours after instillation. No serious adverse effects or adverse effects leading to treatment discontinuation were observed during the study. In the Phase 3 clinical trial in Japan (once-daily instillation for 6 months), no trend toward strengthening of the eyelid-lifting effect or rebound effect was observed. In this clinical study, MRD-1 was defined as the distance from the center of the pupil to the upper eyelid margin, as determined from anterior segment photographs. Upneeq®? (oxymetazoline hydrochlorides ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis ("low-lying lids") in adults. The product was approved in the US by the FDA in July 2020. Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions. UPNEEQ is a type of medication that may affect blood pressure. Upneeq®? activates a muscle in the eyelids, lifting the lid for a more open and awake look. One drop daily is clinically proven to provide visible results in as fast as 5 minutes and lasts up to 8 hours. In July 2020, Osmotica Pharmaceuticals plc (due to a company name change, currently known as RVL Pharmaceuticals Inc.), entered into an exclusive license agreement with Santen, covering the continued development, registration, and commercialization rights for RVL-1201, a 0.1% oxymetazoline hydrochloride ophthalmic solution, in Japan and certain other international markets. Santen has been developing the product as STN1013800.

Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026

Santen Pharmaceutical Co., Ltd. expected to report Q3 2026 results on February 6, 2026. This event was calculated by S&P Global (Created on November 7, 2025).

Santen Pharmaceutical Co., Ltd., ¥ 19.0, Cash Dividend, Mar-30-2026

Santen announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea®? (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the progression of myopia in children. The approval follows the European Commission authorisation and the first launch in Germany earlier this year, with additional launches in Europe to follow. Short-sightedness is rising fast among children in the UK, where many children now live with myopia, more than double the number from 50 years ago. Increased screen time, less outdoor activity, and intensive near work are putting a growing strain on young eyes. Globally, approximately one in three children and adolescents are expected to be affected by 2050. The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise faces at a distance. Myopia can affect learning, confidence, and participation in school and play. Early interventions are key to slowing progression and supporting children's eye health and wellbeing. Childhood myopia increases the risk of severe eye disease later in life. "A comprehensive approach, combining lifestyle habits, optical correction, and approved medical options, gives children the best chance to support healthy vision into adulthood." With over 135 years of experience in eye health, Santen is committed to advancing early intervention and collaboration in paediatric myopia, for happier lives and brighter futures. Ryjunea®? is a registered trademark of Santen Pharmaceutical Co., Ltd. Ryjunea®®? is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. It is backed by the Phase III STAR study, showing that Ryjunea®? significantly reduced the annual progression of myopia with an acceptable safety and tolerability profile. As a low-dose atropine eye drop, administered once daily at bedtime, it provides a convenient way to manage myopia that integrates easily into a child's routine. The product is licensed from Sydnexis Inc. to Santen's Switzerland-based affiliate, Santen SA, for registration and commercialisation across Europe, the Middle East, and Africa (EMEA). It has received market authorisation from the European Commission on June 2, and now from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on October 30.

From October 1, 2025 to November 5, 2025, the company has repurchased 3,224,600 shares, representing 0.96% for ¥4,998.66 million. With this, the company has completed the repurchase of 19,800,000 shares, representing 5.87% for ¥31,896.01 million under the buyback announced on May 13, 2025.

The company closed its plan on November 5, 2025.

Santen Pharmaceutical Co., Ltd., Board Meeting, Nov 06, 2025. Agenda: To consider and approve to cancel treasury shares; and to consider any other matters.

Santen Pharmaceutical Co., Ltd., Q2 2026 Earnings Call, Nov 06, 2025